Search results for "FDA news"
Warnings added to prostate cancer drugs
Talk about health care reform with CMS Administrator Don BerwickPQRI incentive payments now being sentAre you enrolled in PECOS?
https://immattersacp.org/weekly/archives/2010/10/26/7.htm
26 Oct 2010
Recalls of generic drugs raise safety concerns
This issue also includes stories on antibiotic stewardship and point-of-care ultrasound, as well as conference coverage from the American Public Health Association and CHEST.
https://immattersacp.org/archives/2020/01/recalls-of-generic-drugs-raise-safety-concerns.htm
1 Jan 2020
Coumadin samples recalled
Some sample packs of Coumadin (warfarin) have been recalled by the manufacturer because the active ingredient may be below or above therapeutic levels.
https://immattersacp.org/weekly/archives/2010/07/20/9.htm
20 Jul 2010
FDA panel divided on rosiglitazone
A panel that advises the FDA was divided last week in a vote on whether rosiglitazone (Avandia) should be removed from the market.
https://immattersacp.org/weekly/archives/2010/07/20/8.htm
20 Jul 2010
Unapproved prescription cough, cold, allergy meds pulled
ACP Job Placement Center calls for job seekers' profiles
https://immattersacp.org/weekly/archives/2011/03/08/8.htm
8 Mar 2011
Bisphosphonates to carry warning about femur fractures
Put words in our mouth
https://immattersacp.org/weekly/archives/2010/10/19/9.htm
19 Oct 2010
Sibutramine pulled from the market
ACP Members receive QuantiaMD Community Choice AwardsNew ACP Online medical students pageProminent speakers addressed Board of Governors at fall meetingLatest issue of ACP International newsletter online
https://immattersacp.org/weekly/archives/2010/10/19/8.htm
19 Oct 2010
Leflunomide gets new boxed warning
A boxed warning has been added to the label of leflunomide (Arava) highlighting the risk of severe liver injury in patients taking the drug, the FDA announced last week.
https://immattersacp.org/weekly/archives/2010/07/20/10.htm
20 Jul 2010
Opioid manufacturers told to develop physician, patient education
As part of a new federal effort to reduce prescription drug abuse in the U.S., the FDA will begin requiring a Risk Evaluation and Mitigation Strategy (REMS) for all extended-release and long-acting opioid medications.
https://immattersacp.org/weekly/archives/2011/04/26/6.htm
26 Apr 2011